Amplitude VC
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Amplitude VC.
Key people at Amplitude VC.
Key people at Amplitude VC.
Amplitude Ventures is a Canadian venture capital firm specializing in precision medicine, investing at the intersection of biology and artificial intelligence to transform patient care. The firm focuses on building and scaling healthcare startups that develop groundbreaking treatments and technologies across therapeutic areas such as cardiology, oncology, neurology, rare diseases, and drug discovery. With over $500 million in assets under management and offices in Montreal, Toronto, Vancouver, and Calgary, Amplitude supports founders with deep domain expertise and a commitment to improving patient outcomes through innovative healthcare solutions[2][3][4].
Founded in 2018 by former BDC Capital partners Dion Madsen and Jean-François Pariseau, Amplitude Ventures emerged as a spinout focused on healthcare innovation in Canada. The founders leveraged their experience in healthcare investing to create a firm dedicated to precision medicine, combining biology with machine learning. The firm has evolved to include a unique internal engine called Pre-Amp, which incubates and funds early-stage innovations by partnering with academics and entrepreneurs worldwide, accelerating proof-of-concept advancements[1][4][5].
Amplitude Ventures rides the wave of precision medicine and AI-driven healthcare innovation, a rapidly growing sector driven by advances in biology, data science, and machine learning. The timing is critical as healthcare increasingly demands personalized, data-informed treatments that improve diagnostic accuracy and therapeutic efficacy. Amplitude’s focus on Canadian startups helps position the country as a hub for biotech innovation, while their cross-border network amplifies the global impact. By backing companies that integrate biology with AI, Amplitude influences the broader ecosystem by accelerating the translation of scientific breakthroughs into patient-centered solutions[3][4].
Looking ahead, Amplitude Ventures is poised to deepen its impact by expanding its portfolio in emerging therapeutic areas and advancing its Pre-Amp incubation model. Trends such as AI-enabled drug discovery, digital health integration, and personalized therapies will shape their investment strategy. As precision medicine continues to evolve, Amplitude’s influence is likely to grow, fostering innovation that not only benefits patients but also strengthens Canada’s position in the global biotech landscape. Their commitment to transparency, founder partnership, and patient outcomes will remain central to their journey, making them a key player in the future of healthcare investing[3][4].
